retatrutide triple agonist glp-1 gip glucagon receptors Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide vs Tirzepatide: Key Differences

Hermansen K, Bkdal TA, Dring M, Pietraszek A, Mortensen LS, Jrgensen H, Flint A: Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

Dehydration, when paired with muscle fatigue, is thought to be one of the leading contributors to cramping

J Med Food 19:253265 Chowdhury NS, Jamaly S, Farjana F, Begum N, Zenat EA (2019) A review on ethnomedicinal, pharmacological, phytochemical and pharmaceutical profile of ladys finger (Abelmoschus esculentus L.) plant

How Much Water Do I Need